Birchbrook’s Regeneron Pharmaceuticals REGN Stock Holding History

Birchbrook’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.73K	Hold	14	–	–	﹤0.01%	211
2026 Q1	$10.8K	Hold	14	–	–	0.01%	191
2025 Q4	$10.8K	Hold	14	–	–	0.01%	199
2025 Q3	$7.87K	Hold	14	–	–	﹤0.01%	200
2025 Q2	$7.35K	Hold	14	–	–	﹤0.01%	203
2025 Q1	$8.88K	Hold	14	–	–	0.01%	196
2024 Q4	$9.97K	Hold	14	–	–	0.01%	201
2024 Q3	$14.7K	Hold	14	–	–	0.01%	168
2024 Q2	$14.7K	Hold	14	–	–	0.01%	177
2024 Q1	$13.5K	Hold	14	–	–	0.01%	187
2023 Q4	$12.3K	Buy	+14	New	+$11.5K	0.01%	196

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

MCI

McDonald Capital Investors Orinda, California $1.37B AUM 1.88% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Birchbrook's REGN Position: Q2 2026 in Review

Birchbrook held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 14 shares worth $8.73K. The position accounts for ﹤0.01% of the portfolio, ranked #211.

Birchbrook first reported a position in REGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $14.7K in Q3 2024. 518 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Birchbrook held 14 shares of Regeneron Pharmaceuticals worth $8.73K as of Q2 2026.
Birchbrook left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up ﹤0.01% of Birchbrook's portfolio in Q2 2026, its #211 holding.
Birchbrook first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
Birchbrook's Regeneron Pharmaceuticals position peaked at $14.7K in Q3 2024.
518 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Birchbrook's 13F filing for Q2 2026, filed 9 Jul 2026.